Earnings Feed
Start Free
|4May 10, 5:03 PM ET

McKechnie William Edward 4

4 · Lexaria Bioscience Corp. · Filed May 10, 2024

Insider Transaction Report

Form 4
Period: 2024-04-26
Lexaria Bioscience Corp.LEXX
McKechnie William Edward
Director
Transactions
  • Award

    Stock Options

    2024-04-26+5,000→ 40,000 total
    Exercise: $2.36From: 2024-04-26Exp: 2029-04-26→ Common Shares (5,000 underlying)
Holdings

  • Stock Options

    Exercise: $1.96From: 2022-10-12Exp: 2027-10-12→ Common Shares (18,200 underlying)
    30,000

  • common shares

    13,191

  • Stock Options

    Exercise: $3.00From: 2021-04-26Exp: 2026-04-26→ Common Shares (1,500 underlying)
    1,500

  • Stock Options

    Exercise: $3.00From: 2021-06-08Exp: 2026-06-08→ Common Shares (5,000 underlying)
    6,500

  • Stock Options

    Exercise: $3.00From: 2021-09-01Exp: 2026-09-01→ Common Shares (1,900 underlying)
    8,400

  • Stock Options

    Exercise: $3.39From: 2022-03-08Exp: 2027-03-08→ Common Shares (3,400 underlying)
    11,800

  • Stock Options

    Exercise: $0.87From: 2023-07-25Exp: 2028-07-25→ Common Shares (5,000 underlying)
    35,000
Footnotes (3)
  • [F1]Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
  • [F2]Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
  • [F3]Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT